Roots
Analysis
To order this 375+
page report, which features 180+ figures and 195+ tables, please visit this -
https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html
Key Market Insights
§ Over 240 companies across the globe claim to
have the required capabilities to offer variety of services on a contract
basis, working at different scales of operation, for a wide range of ophthalmic
APIs and drug FDFs
§ The market is fragmented, featuring the
presence of both established players and small firms based in different
geographies that claim to be capable of manufacturing ophthalmic products
§ Presently, majority of the CMOs are offering
services for ophthalmic drug FDFs packaged in a variety of formats; popular
types of containers include glass / plastic bottles, ointment tubes and
ampoules / vials
§ In order to acquire competencies across the
supply chain and cater to evolving needs of sponsors, companies have
established presence across different regions, having been certified by various
regulatory authorities
§ Several
players involved in this domain are steadily expanding their capabilities in
order to enhance their respective service portfolios and maintain a competitive
edge
§ In the past few years, over 10,700 trials,
enrolling approximately 4.6 million patients, suffering from a wide range of
chronic eye conditions, have been registered across the globe by different
sponsors
§ Most of the installed, global ophthalmic drug
manufacturing capacity belongs to larger and more established CMOs, accounting
for over 80% of available capacity across various geographies
§ The demand for manufacturing services for
ophthalmic drug products is expected to increase in the coming years; we
believe stakeholders may have to expand their respective capacities to ensure
consistent supply
§ We
expect ophthalmic drug developers to continue to outsource their development
and manufacturing operations in the short to mid-term, causing service-based
revenues to grow at an annualized rate of over 8%
§ In the
long-term, the projected opportunity is anticipated to be well distributed
across various packaging formats, scales of operation and sizes of contract
service providers
§ Eminent representatives from prominent
ophthalmic drug contract manufacturing companies confirm the importance of
outsourcing, highlighting prevalent and anticipated trends within this domain
For more information, please visit https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html
Table of Contents
1.1. Scope
of the Report
1.2. Research
Methodology
1.3. Chapter
Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Context and Background
3.2. Introduction to Ophthalmology
3.2.1. Chronic Eye Conditions and Associated
Economic Burden
3.3. Common Ophthalmic Drug Dosage
Forms
3.3.1. Types of Oral Drug Formulations
3.3.1.1. Tablets
3.3.1.2. Capsules
3.3.1.3. Eye Supplements
3.3.2. Types of Semi-solid Formulations
3.3.2.1. Ointments
3.5.2.2. Gels
3.5.2.3. Emulsions
3.3.3. Types of Liquid Drug Formulations
3.3.3.1. Solutions
3.3.3.2. Suspensions
3.5.3.1. Sterile Injectables
3.3.4. Intraocular Inserts
3.4. Common Primary Packaging Formats
for Ophthalmic Drugs
3.5. Overview of Contract Manufacturing
3.6. Outsourcing in the Ophthalmology
Industry
3.6.1. Need for Outsourcing
3.6.2. Commonly Outsourced Operations
3.6.3. Guidelines for Selecting a Contract
Manufacturing Organization (CMO) Partner
3.6.4. Advantages of Outsourcing
Manufacturing Operations
3.6.5. Challenges Associated with Ophthalmic
Drugs Contract Manufacturing
3.6.6. Growth Drivers and Roadblocks to
Ophthalmic Drugs Contract Manufacturing
3.6.7. Recent Developments and Upcoming
Trends
4. CURRENT MARKET LANDSCAPE
4.1.
Chapter Overview
4.2. Ophthalmic Drug Contract
Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Geographical Location
4.2.5. Analysis by Location of Manufacturing
Facilities
4.2.6. Analysis by Type of Product
4.2.7. Analysis by Type of FDF Manufactured
4.2.8. Analysis by Type of Primary Packaging
4.2.9. Analysis by Type of Service(s)
Offered
4.2.10. Analysis by Regulatory Accreditations /
Certifications
5. COMPANY COMPETITVENESS ANALYSIS
5.1. Chapter
Overview
5.2. Key
Assumptions and Methodology
5.3. Competitiveness
Analysis: Ophthalmic API Contract Manufacturers
5.3.1. Ophthalmic API Contract Manufacturers in North America
5.4. Competitiveness
Analysis: Ophthalmic Drug FDF Contract Manufacturers
5.4.1. Ophthalmic Drug FDF Contract Manufacturers in North America
6. OPHTHALMIC DRUGS CONTERACT
MANUFACTURING IN NORTH AMERICA: COMPANY PROFILES
6.1. Chapter
Overview
6.2. Akorn
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Service Portfolio
6.2.4. Recent Developments and Future
Outlook
7. OPHTHALMIC DRUGS CONTERACT
MANUFACTURING IN EUROPE: COMPANY PROFILES
7.1. Chapter
Overview
7.2. FARMIGEA
7.2.1. Company Overview
7.2.2. Service Portfolio
7.2.3. Recent Developments and Future
Outlook
7.3. Lomapharm
7.3.1. Company Overview
7.3.2. Service Portfolio
7.3.3 Recent Developments and Future
Outlook
7.4. Medichem
7.4.1. Company Overview
7.4.2. Service Portfolio
7.4.3. Recent Developments and Future
Outlook
7.5. Recipharm
7.5.1. Company Overview
7.5.2. Financial Information
7.5.3. Service Portfolio
7.5.4. Recent Developments and Future
Outlook
7.6. Salvat
7.6.1. Company Overview
7.6.2 Service Portfolio
7.6.3. Recent Developments and Future
Outlook
8. OPHTHALMIC DRUGS CONTERACT
MANUFACTURING IN ASIA-PACIFIC: COMPANY PROFILES
8.1. Chapter Overview
8.2. Akums
8.2.1. Company Overview
8.2.2. Service Portfolio
8.2.3. Recent Developments and Future
Outlook
8.3. Bal Pharma
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Service Portfolio
8.2.4. Recent Developments and Future
Outlook
8.4. Entod Pharmaceuticals
8.4.1. Company Overview
8.4.2. Service Portfolio
8.4.3. Recent Developments and Future
Outlook
8.5. Glenmark Pharmaceuticals
8.5.1. Company Overview
8.5.2. Service Portfolio
8.5.3. Recent Developments and Future
Outlook
8.6. Indiana Ophthalmics
8.6.1. Company Overview
8.6.2. Service Portfolio
8.6.3. Recent Developments and Future
Outlook
8.7. Sunways India
8.7.1. Company Overview
8.7.2. Service Portfolio
8.7.3. Recent Developments and Future
Outlook
9. CLINICAL TRIAL ANALYSIS
9.1. Chapter
Overview
9.2. Scope
and Methodology
9.3. Ophthalmic
Drug Trial Analysis
9.3.1. Analysis
by Trial Registration Year
9.3.2. Geographical
Analysis by Number of Clinical Trials
9.3.3. Geographical
Analysis by Enrolled Patient Population
9.3.4. Analysis
by Phase of Development
9.3.5. Analysis
by Trial Recruitment Status
9.3.6. Analysis
by Type of Sponsor / Collaborator
9.3.7. Most
Active Players in Terms of Number of Registered Trials
9.3.8. Analysis
by Type of Intervention
9.3.9. Analysis
by Trial Focus
9.3.10. Analysis
by Target Indication
9.3.11. Benchmark
Analysis of Active Industry Players
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
